GLP-1 RAs decreased the risk of mortality from cardiovascular causes (RR: 0.90; 95% CI: 0.83-0.97; P = 0.004) and fatal or nonfatal stroke (RR: 0.85; 95% CI: 0.77-0.94; P = 0.001) when compared to placebo controls. This evidence concerns the gene GLP1R and Stroke.